Alvaro, A., R. Solà, R. Rosales, J. Ribalta, A. Anguera, L. Masana & J. C. Vallvé (2008) Gene expression analysis of a human enterocyte cell line reveals downregulation of cholesterol biosynthesis in response to short-chain fatty acids. IUBMB Life, 60, 757-64.

Berger, J., A. Pujol, P. Aubourg & S. Forss-Petter (2010) Current and future pharmacological treatment strategies in X-linked adrenoleukodystrophy. Brain Pathol, 20, 845-56.

Butzner, J. D., R. Parmar, C. J. Bell & V. Dalal (1996) Butyrate enema therapy stimulates mucosal repair in experimental colitis in the rat. Gut, 38, 568-73.

Cook, S. I. & J. H. Sellin (1998) Review article: short chain fatty acids in health and disease. Aliment Pharmacol Ther, 12, 499-507.

Cummings, J. H., E. W. Pomare, W. J. Branch, C. P. Naylor & G. T. Macfarlane (1987) Short chain fatty acids in human large intestine, portal, hepatic and venous blood. Gut, 28, 1221-7.

den Besten, G., K. van Eunen, A. K. Groen, K. Venema, D. J. Reijngoud & B. M. Bakker (2013) The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism. J Lipid Res, 54, 2325-40.

Deroanne, C. F., K. Bonjean, S. Servotte, L. Devy, A. Colige, N. Clausse, S. Blacher, E. Verdin, J. M. Foidart, B. V. Nusgens & V. Castronovo (2002) Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene, 21, 427-36.

Di Sabatino, A., R. Morera, R. Ciccocioppo, P. Cazzola, S. Gotti, F. P. Tinozzi, S. Tinozzi & G. R. Corazza (2005) Oral butyrate for mildly to moderately active Crohn’s disease. Aliment Pharmacol Ther, 22, 789-94.

Endesfelder, D., M. Engel, A. G. Davis-Richardson, A. N. Ardissone, P. Achenbach, S. Hummel, C. Winkler, M. Atkinson, D. Schatz, E. Triplett, A. G. Ziegler & W. zu Castell (2016) Towards a functional hypothesis relating anti-islet cell autoimmunity to the dietary impact on microbial communities and butyrate production. Microbiome, 4, 17.

Fung, K. Y., L. Cosgrove, T. Lockett, R. Head & D. L. Topping (2012) A review of the potential mechanisms for the lowering of colorectal oncogenesis by butyrate. Br J Nutr, 108, 820-31.

Gao, Z., J. Yin, J. Zhang, R. E. Ward, R. J. Martin, M. Lefevre, W. T. Cefalu & J. Ye (2009) Butyrate improves insulin sensitivity and increases energy expenditure in mice. Diabetes, 58, 1509-17.

Gardian, G., S. E. Browne, D. K. Choi, P. Klivenyi, J. Gregorio, J. K. Kubilus, H. Ryu, B. Langley, R. R. Ratan, R. J. Ferrante & M. F. Beal (2005) Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington’s disease. J Biol Chem, 280, 556-63.

Hallert, C., I. Björck, M. Nyman, A. Pousette, C. Grännö & H. Svensson (2003) Increasing fecal butyrate in ulcerative colitis patients by diet: controlled pilot study. Inflamm Bowel Dis, 9, 116-21.

Hamer, H. M., D. Jonkers, K. Venema, S. Vanhoutvin, F. J. Troost & R. J. Brummer (2008) Review article: the role of butyrate on colonic function. Aliment Pharmacol Ther, 27, 104-19.

Hofmanová, J., A. Vaculová, Z. Koubková, M. Hýzd’alová & A. Kozubík (2009) Human fetal colon cells and colon cancer cells respond differently to butyrate and PUFAs. Mol Nutr Food Res, 53 Suppl 1, S102-13.

Joseph, J., N. Wajapeyee & K. Somasundaram (2005) Role of p53 status in chemosensitivity determination of cancer cells against histone deacetylase inhibitor sodium butyrate. Int J Cancer, 115, 11-8.

Kim, H. J., P. Leeds & D. M. Chuang (2009) The HDAC inhibitor, sodium butyrate, stimulates neurogenesis in the ischemic brain. J Neurochem, 110, 1226-40.

Li, H., L. Myeroff, D. Smiraglia, M. F. Romero, T. P. Pretlow, L. Kasturi, J. Lutterbaugh, R. M. Rerko, G. Casey, J. P. Issa, J. Willis, J. K. Willson, C. Plass & S. D. Markowitz (2003) SLC5A8, a sodium transporter, is a tumor suppressor gene silenced by methylation in human colon aberrant crypt foci and cancers. Proc Natl Acad Sci U S A, 100, 8412-7.

Lin, H. V., A. Frassetto, E. J. Kowalik, A. R. Nawrocki, M. M. Lu, J. R. Kosinski, J. A. Hubert, D. Szeto, X. Yao, G. Forrest & D. J. Marsh (2012) Butyrate and propionate protect against diet-induced obesity and regulate gut hormones via free fatty acid receptor 3-independent mechanisms. PLoS One, 7, e35240.

Lupton, J. R. (2004) Microbial degradation products influence colon cancer risk: the butyrate controversy. J Nutr, 134, 479-82.

Machiels, K., M. Joossens, J. Sabino, V. De Preter, I. Arijs, V. Eeckhaut, V. Ballet, K. Claes, F. Van Immerseel, K. Verbeke, M. Ferrante, J. Verhaegen, P. Rutgeerts & S. Vermeire (2014) A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis. Gut, 63, 1275-83.

Meijer, K., P. de Vos & M. G. Priebe (2010) Butyrate and other short-chain fatty acids as modulators of immunity: what relevance for health? Curr Opin Clin Nutr Metab Care, 13, 715-21.

Miller, A. A., E. Kurschel, R. Osieka & C. G. Schmidt (1987) Clinical pharmacology of sodium butyrate in patients with acute leukemia. Eur J Cancer Clin Oncol, 23, 1283-7.

Nylund, L., M. Nermes, E. Isolauri, S. Salminen, W. M. de Vos & R. Satokari (2015) Severity of atopic disease inversely correlates with intestinal microbiota diversity and butyrate-producing bacteria. Allergy, 70, 241-4.

Perrine, S. P., G. D. Ginder, D. V. Faller, G. H. Dover, T. Ikuta, H. E. Witkowska, S. P. Cai, E. P. Vichinsky & N. F. Olivieri (1993) A short-term trial of butyrate to stimulate fetal-globin-gene expression in the beta-globin disorders. N Engl J Med, 328, 81-6.

Plöger, S., F. Stumpff, G. B. Penner, J. D. Schulzke, G. Gäbel, H. Martens, Z. Shen, D. Günzel & J. R. Aschenbach (2012) Microbial butyrate and its role for barrier function in the gastrointestinal tract. Ann N Y Acad Sci, 1258, 52-9.

Qin, J., Y. Li, Z. Cai, S. Li, J. Zhu, F. Zhang, S. Liang, W. Zhang, Y. Guan, D. Shen, Y. Peng, D. Zhang, Z. Jie, W. Wu, Y. Qin, W. Xue, J. Li, L. Han, D. Lu, P. Wu, Y. Dai, X. Sun, Z. Li, A. Tang, S. Zhong, X. Li, W. Chen, R. Xu, M. Wang, Q. Feng, M. Gong, J. Yu, Y. Zhang, M. Zhang, T. Hansen, G. Sanchez, J. Raes, G. Falony, S. Okuda, M. Almeida, E. LeChatelier, P. Renault, N. Pons, J. M. Batto, Z. Zhang, H. Chen, R. Yang, W. Zheng, H. Yang, J. Wang, S. D. Ehrlich, R. Nielsen, O. Pedersen & K. Kristiansen (2012) A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature, 490, 55-60.

Raqib, R., P. Sarker, P. Bergman, G. Ara, M. Lindh, D. A. Sack, K. M. Nasirul Islam, G. H. Gudmundsson, J. Andersson & B. Agerberth (2006) Improved outcome in shigellosis associated with butyrate induction of an endogenous peptide antibiotic. Proc Natl Acad Sci U S A, 103, 9178-83.

Rivière, A., M. Selak, D. Lantin, F. Leroy & L. De Vuyst (2016) Bifidobacteria and Butyrate-Producing Colon Bacteria: Importance and Strategies for Their Stimulation in the Human Gut. Front Microbiol, 7, 979.

Sanderson, I. R. & S. Naik (2000) Dietary regulation of intestinal gene expression. Annu Rev Nutr, 20, 311-38.

Scheppach, W., H. Sommer, T. Kirchner, G. M. Paganelli, P. Bartram, S. Christl, F. Richter, G. Dusel & H. Kasper (1992) Effect of butyrate enemas on the colonic mucosa in distal ulcerative colitis. Gastroenterology, 103, 51-6.

Scheppach, W. & F. Weiler (2004) The butyrate story: old wine in new bottles? Curr Opin Clin Nutr Metab Care, 7, 563-7.

Sher, G. D., G. D. Ginder, J. Little, S. Yang, G. J. Dover & N. F. Olivieri (1995) Extended therapy with intravenous arginine butyrate in patients with beta-hemoglobinopathies. N Engl J Med, 332, 1606-10.

Sunkara, L. T., M. Achanta, N. B. Schreiber, Y. R. Bommineni, G. Dai, W. Jiang, S. Lamont, H. S. Lillehoj, A. Beker, R. G. Teeter & G. Zhang (2011) Butyrate enhances disease resistance of chickens by inducing antimicrobial host defense peptide gene expression. PLoS One, 6, e27225.

Takahashi, K., A. Nishida, T. Fujimoto, M. Fujii, M. Shioya, H. Imaeda, O. Inatomi, S. Bamba, M. Sugimoto & A. Andoh (2016) Reduced Abundance of Butyrate-Producing Bacteria Species in the Fecal Microbial Community in Crohn’s Disease. Digestion, 93, 59-65.

Van Immerseel, F., R. Ducatelle, M. De Vos, N. Boon, T. Van De Wiele, K. Verbeke, P. Rutgeerts, B. Sas, P. Louis & H. J. Flint (2010) Butyric acid-producing anaerobic bacteria as a novel probiotic treatment approach for inflammatory bowel disease. J Med Microbiol, 59, 141-3.

Vecsey, C. G., J. D. Hawk, K. M. Lattal, J. M. Stein, S. A. Fabian, M. A. Attner, S. M. Cabrera, C. B. McDonough, P. K. Brindle, T. Abel & M. A. Wood (2007) Histone deacetylase inhibitors enhance memory and synaptic plasticity via CREB:CBP-dependent transcriptional activation. J Neurosci, 27, 6128-40.

Vernia, P., V. Annese, G. Bresci, G. d’Albasio, R. D’Incà, S. Giaccari, M. Ingrosso, C. Mansi, G. Riegler, D. Valpiani, R. Caprilli & G. I. p. l. S. d. C. a. d. Retto (2003) Topical butyrate improves efficacy of 5-ASA in refractory distal ulcerative colitis: results of a multicentre trial. Eur J Clin Invest, 33, 244-8.

Yadav, H., J. H. Lee, J. Lloyd, P. Walter & S. G. Rane (2013) Beneficial metabolic effects of a probiotic via butyrate-induced GLP-1 hormone secretion. J Biol Chem, 288, 25088-97.

Zeitlin, P. L. (2000) Future pharmacological treatment of cystic fibrosis. Respiration, 67, 351-7.